Our findings demonstrate that administration of HSA-Trx elicits preventive and therapeutic effects on HFD-induced NASH pathogenesis by exerting anti-oxidative, anti-inflammatory, and anti-apoptotic effects. Here, TXN is linked to metabolic dysfunction-associated steatohepatitis.